Clinical Trials Logo

Hypertrophy clinical trials

View clinical trials related to Hypertrophy.

Filter by:

NCT ID: NCT03890692 Not yet recruiting - Adenoid Hypertrophy Clinical Trials

Methods of Assessment of Adenoid Size

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Chronic nasal obstruction due to adenoid hypertrophy is among the most common health problems affecting children, and adenoidectomy is one of the most common surgical procedures performed in this age group Because of difficulties associated with the use of the objective methods (such as nasopharyngeal endoscopy) in young children, the development of a reliable scale based on the child's symptoms to properly evaluate the need for surgical intervention would be of great value for clinicians. When adenoidectomy is being considered, the diagnosis and documentation of adenoidal hypertrophy become an important issue. Numerous modalities have been used for this task, including trans oral digital palpation and trans oral mirror examination; however, these methods are quite impractical with uncooperative younger children

NCT ID: NCT03877731 Completed - Clinical trials for Hypertrophic Obstructive Cardiomyopathy

Mitral Valve in Hypertrophic Cardiomyopathy

Start date: December 1, 2006
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical treatment modality to relieve outflow tract obstruction in such patients

NCT ID: NCT03870165 Completed - Hypertrophy Clinical Trials

Food First Approach to Stimulate Muscle Protein Synthesis in Healthy Adults

Salmon
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 3.5 oz of Salmon fillet or its constituent macronutrients as isolated amino acids and fat. Repeated blood and breath samples as well as muscle biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid transporters, anabolic signalling and myofibrillar protein synthesis rates during the trials

NCT ID: NCT03854279 Recruiting - Clinical trials for Tonsillar Hypertrophy, Tonsillitis

Comparison of Bizact With Electroscissor for Tonsillectomy

Start date: February 20, 2019
Phase: Phase 4
Study type: Interventional

In a randomized, partly double-blind prospective setup we want to compare traditional adult electro-scissor tonsillectomy With ultrasound Technology, Bizact.

NCT ID: NCT03850119 Not yet recruiting - Hypertrophic Scar Clinical Trials

Nanofat on Wound Healing and Scar Formation

NFWHSF
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This study will evaluate the effectiveness and safety of intradermal injection of Nanofat on wound healing and scar formation.

NCT ID: NCT03849274 Completed - Knee Arthropathy Clinical Trials

SMART Dressing for Hypertrophic Scar Treatment Post-Total Knee/Hip Arthroplasty

Start date: January 31, 2020
Phase: Early Phase 1
Study type: Interventional

Pressure therapy (PT) and silicone therapy are recommended as first-line non-invasive treatment for Hypertrophic Scar (HS), yet the effectiveness of the combination of these two treatments through an RCT trial has not been established yet. This study aims to examine the effectiveness of the combination of adequate pressure therapy and silicone gel sheeting implemented by Smart Scar Care Pad (SSCP) + conventional Pressure Garment (PG) versus conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR). This study also aims to find out the prevalence of hypertrophic scar among patients with THR and TKR. This study is a randomised controlled trial with two parallel arms, with allocation ratio (Experimental: Control) of 1: 1 in order to establish the superiority of SSCP + PG over PG. Subjects with hypertrophic scar will be randomly assigned to either treatment or control group. The subjects in the treatment group will be provided with the SSCP and PG for treatment, whereas the subjects in the control group will be prescribed only the PG. The treatment will last for a total of 6 months. A variety of objective outcome measures will be used to analysis the treatment effect.

NCT ID: NCT03846297 Recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy

OPTIM-HCM
Start date: September 23, 2020
Phase:
Study type: Observational

The main objective of the study is to improve implantable cardioverter defibrillator (ICD) implantation decision-making processing relevance by developing a new prediction model of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM), including newly identified potential biomarkers by magnetic resonance imaging (MRI) and genetics, through a prospective nationwide study, multivariate analysis and modelling of an absolute risk. The secondary objective is to perform a medico-economic analysis of ICD implantation in order to define an optimal rule for ICD implantation in patients with HCM, taking into account the benefits of ICD, adverse effects of ICD and associated costs (cost of quality adjusted life years saved).

NCT ID: NCT03842163 Completed - Clinical trials for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

TTRACK
Start date: July 9, 2018
Phase:
Study type: Observational

The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) >15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol

NCT ID: NCT03841305 Recruiting - Clinical trials for Liver Metastasis Colon Cancer

Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

HYPER-LIV01
Start date: April 29, 2019
Phase: Phase 2
Study type: Interventional

The hypothesis is that liver venous deprivation (LVD) could strongly improve hypertrophy of the future remnant liver (FRL) at 3 weeks, as compared to portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.

NCT ID: NCT03832660 Completed - Clinical trials for Hypertrophic Cardiomyopathy

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

SILICOFCM
Start date: May 3, 2019
Phase: Phase 2
Study type: Interventional

The overall aim of this project is to establish potential benefits of a novel lifestyle (physical activity and dietary nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor) interventions in patients with hypertrophic cardiomyopathy (HCM). HCM is the most common genetic cardiovascular disease with a broad spectrum of disease severity. Angiotensin receptor neprilysin inhibitor reduces death, hospitalisation, and may improve cardiac function and exercise tolerance in heart failure. Exercise training is associated with a significant increase in exercise tolerance, but appear to have limited effect on measures of cardiac morphology or function in patients with HCM. Dietary supplementation with inorganic nitrate (i.e. concentrated nitrate-rich beetroot juice) improves exercise capacity, vasodilatation and cardiac output reserves while reduces arterial wave reflections, which are linked to left ventricular diastolic dysfunction and remodelling. Using a five-centre, open label, three-arm, pilot design, the present study will evaluate the effect of lifestyle (physical activity and dietary supplementation with inorganic nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor sacubitril / valsartan) interventions in patients with HCM. The Aim is to examine whether these interventions improve functional capacity, clinical phenotypic characteristics, and quality of life in patients with HCM.